CXCR4 antagonist treatment of hematopoietic cells

Patent Number: 7,435,718

Date of First Priority Issue: Tuesday May 9th, 2000

Date Issued: Tuesday October 14th, 2008

Assignee: Chemokine Therapeutics Corp. (CA); The University of British Columbia (CA)

Inventors: Tudan; Christopher R. (Vancouver, CA), Merzouk; Ahmed (Richmond, CA), Arab; Lakhdar (Vancouver, CA), Saxena; Geeta (Vancouver, CA), Eaves; Connie J. (Vancouver, CA), Cashman; Johanne (Vancouver, CA), Richter, legal representative; Mary A. (Vancouver, CA),

From Class: Mobilization

Comments: No comments

This is a composition of matter patent covering chemical antagonists of the receptor CXCR-4. This receptor binds to stromal derived factor (SDF-1, otherwise known as CXCL12) and maintains the hematopoietic stem cells in the bone marrow. When the receptor is antagonized the hematopoietic stem cells mobilize into circulation. This can be used for collecting hematopoietic stem cells for transplantation without needing to drill holes in the bones of donors. Additionally, one may want to antagonize CXCR-4 in order to mobilize stem cells after a heart attack or stroke, so as to allow a more rapid healing of the injured tissue.

View this patent on the USPTO website.

Added to StemCellPatents.com on Sunday October 19th, 2008

Social & Bookmarking: